Postpartum Depression

Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic psychedelic compound aimed at treating postpartum depression (PPD.)  The company, which...

Reunion Neuroscience (NASDAQ: REUN) no longer meets the minimum required $1.00 per-common-share for continued listing on the Nasdaq. The psychedelic biotech company started trading in October 2020 at $10.84 a share. It achieved its highest point on July 2021 ($32.50), but the price slipped...

Clinical-stage psychedelics biotech Reunion Neuroscience Inc. (NASDAQ: REUN) shared its unaudited financial results for the third quarter, as of Dec. 31, 2022. Cash and investments totaled $24.3 (CA$32.4) million by December 31, 2022. For the three and nine-month periods, R&D expenses were $2.6...

Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) announced it is undertaking a Phase 1 clinical trial on RE104, which is a novel serotonergic substance that could treat postpartum depression.  32 healthy participants were divided into four ascending-dose...

Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) reported its business update and fiscal results for the second quarter ended September 30, 2022. Reunion’s president and CEO Greg Mayes stated that the company has consolidated as an independent company and is “well...

This article was originally published on Psychedelic Spotlight and appears here with permission. Postpartum depression impacts thousands with no good treatment options. Some people are now treating postpartum depression with psychedelics Despite impacting 1 in 7 women (and 1 in 10 men) postpartum...

The FDA has signed off Lipocine Inc's (NASDAQ: LPCN) Investigational New Drug Application (IND) to initiate a Phase 2 study to evaluate LPCN 1154 for the treatment of postpartum depression (PPD) in adults. A pharmacokinetic (PK) study to assess dose proportionality is planned to...